SciELO - Scientific Electronic Library Online

 
vol.19 número12Empleo del clavo intramedular de Küntscher en pacientes con fracturas diafisarias de tibiaEstilos de vida e infección por cólera en la provincia de Santiago de Cuba índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


MEDISAN

versión On-line ISSN 1029-3019

Resumen

MARTINEZ FERIA, Francisco; ACOSTA BROOKS, Soraida Cándida  y  COBIAN CABALLERO, Carlos Oliver. Progression-free survival of non-small cells lung cancer in patients vaccinated with CIMAvax-EGF. MEDISAN [online]. 2015, vol.19, n.12, pp. 1485-1491. ISSN 1029-3019.

An observational, descriptive and longitudinal study during a first time, and analytic case-control study in a second time, of 95 patients with non small cells lung cancer, in advanced stages (IIIB-IV) and of the epidermoid carcinoma and adenocarcinoma histological subtypes who were treated with the vaccine CIMAvax-EGF in the Department of Clinical Assays of “Saturnine Lora Torres” Teaching Clinical Surgical Provincial Hospital, and in “30 de Noviembre”, “28 de Septiembre”, “José Martí” and “Camilo Torres” polyclinics in Santiago de Cuba province, was carried out in the period 2006-2013, in order to estimate the progression-free survival of the clinical entity in them.  After a year of the vaccination, the probability of progression-free survival was just 30.5%, which was significantly higher in stage IIIB patients, with a favourable response to the first treatment line, after treated with a chemotherapy-radiotherapy combination and bovine CIMAvax-EGF, whenever 4 or more immunizations were used

Palabras clave : progression-free survival; lung cancer; vaccine against cancer; CIMAvax-EGF.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License